GlassScriptPhysician profile
Julie Webster
NPI 1225038748
$2,918.91
in general payments reported to CMS, 2019-2025
28 companies · $940 in 2025
The $940 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $241 · 2021: $35.99 · 2022: $182 · 2023: $204 · 2024: $515 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280 · Travel and Lodging: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,279.80 |
| Travel and Lodging | $378.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gentleman Orthopedic Solutions | $691.68 | 2024-2025 | |
| Biotissue Holdings INC. | $403.89 | 2022-2025 | |
| Organogenesis INC. | $319.85 | 2019-2021 | |
| Melinta Therapeutics, LLC | $165.31 | 2019 | |
| Stryker Corporation | $150.09 | 2019 | |
| Arthrex, INC. | $126.58 | 2025 | |
| Endologix LLC | $114.18 | 2019 | |
| Smith+Nephew, INC. | $106.95 | 2019-2024 | Collagenase Santyl, Regranex |
| Amgen INC. | $102.30 | 2024-2025 | Krystexxa |
| Kerecis Limited | $68.17 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Nevro Corp. | $63.90 | 2023-2024 | Senza |
| Sandoz INC. | $53.08 | 2019-2020 | |
| Boston Scientific Corporation | $52.13 | 2019-2024 | Patient Trial Kit, Wavewriter Alpha Prime 16 |
| Reprise Biomedical, INC. | $49.77 | 2024 | Miro3d |
| Orthofix Medical, INC. | $47.99 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $45.99 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Abbvie INC. | $43.34 | 2024-2025 | |
| Horizon Therapeutics Plc | $41.85 | 2019 | |
| Averitas Pharma INC. | $41.66 | 2023 | Qutenza |
| Zyla Life Sciences, INC. | $41.31 | 2019-2020 | |
| Treace Medical Concepts, INC. | $39.37 | 2025 | |
| Acera Surgical, INC. | $33.88 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $32.96 | 2019-2024 | Nuzyra |
| Vertex Pharmaceuticals Incorporated | $26.54 | 2025 | |
| Abbott Laboratories | $17.68 | 2024 | Proclaim |
| Osiris Therapeutics INC. | $15.82 | 2019 | |
| Advanced Oxygen Therapy INC. | $11.57 | 2024 | Topical Oxygen Chamber For Extremities |
| Merck Sharp & Dohme LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.